Sec Form 4 Filing - Geist William @ BIO-TECHNE Corp - 2023-08-15

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Geist William 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) PRESIDENT, PROTEIN SCIENCES (Last) (First) (Middle) 614 MCKINLEY PL N E 3. Date of Earliest Transaction (MM/DD/YY) 08/15/2023 (Street) MINNEAPOLIS, MN55413 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 9,960 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 2 ) ( 3 ) ( 3 ) Common Stock 7,140 7, 140 D Stock Options (Right to Buy) $ 94.52 ( 3 ) 08/15/2029 Common Stock 22,200 22,200 D Stock Options (Right to Buy) $ 94.52 ( 4 ) 08/15/2029 Common Stock 29,600 29,600 D Restricted Stock Units ( 2 ) ( 3 ) ( 3 ) Common Stock 3,360 3,360 D Stock Options (Right to Buy) $ 100.39 ( 3 ) 02/01/2029 Common Stock 11,936 11,936 D Stock Options (Right to Buy) $ 100.39 ( 5 ) 02/01/2029 Common Stock 15,912 15,912 D Restricted Stock Units ( 2 ) 08/15/2023 A 8,377 ( 6 ) ( 6 ) Common Stock 8,377 $ 0 8,377 D Stock Options (Right to Buy) $ 84.61 08/15/2023 A 22,544 ( 6 ) 08/15/2030 Common Stock 22,544 $ 0 22,544 D Stock Options (Right to Buy) $ 84.61 08/15/2023 A 30,059 ( 7 ) 08/15/2030 Common Stock 30,059 $ 0 30,059 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Geist William 614 MCKINLEY PL N E MINNEAPOLIS, MN55413 PRESIDENT, PROTEIN SCIENCES Signatures /s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed 08/17/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents 6,640 shares of restricted stock for which the risk of forfeiture will lapse as to 3,320 shares on each of February 1, 2024 and February 1, 2025. ( 2 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 3 )Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 4 )Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026. ( 5 )Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 3,976 shares vest on each of 2/1/2025 and 2/1/2026. ( 6 )Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 7 )Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.

Remarks: On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.